Lillian Brown

@ajlamesa I spent a week taking only public transit in Mexico City on my own with my 5 and 7 year old. So much more pleasant than the US experience even during rush hour.

Over the past month, I've used trains and buses in Puerto Vallarta/Nayarit, Guadalajara, Morelia, Mexico City, and Merida. There has been zero yelling, drug use, threatening behavior, or other transgressions that plague U.S. transit systems. Most of the people riding these transit systems are working-class Mexicans, which means they have fewer monetary resources than many of the individuals who routinely disrupt U.S. systems. What we tolerate on U.S. transit systems is absolutely intolerable. People engaged in drug use or threatening behavior need to be immediately removed from stations or transit systems by armed police officers. They need to be temporarily banned from using the systems and removed again if they return. Enough is enough.

Yesterday, at the International AIDS Conference (#AIDS2024) in Munich, we got one of those thrilling moments you hope for when attending a scientific conference -- but don't usually get! Here's what happened. @LindaGailBekker @drmoupali blogs.jwatch.org/hiv-id-observa…

Looking forward to PURPOSE-2 results in gender-diverse individuals! #preventionwithpurpose

Great write up of the PURPOSE-1 results by @PaulSaxMD highlighting the incredible results and the many innovative aspects of the trial design blogs.jwatch.org/hiv-id-observa…

👏 @DTHF_SA’s @LindaGailBekker 🇿🇦 receives a standing ovation after presenting full results from the PURPOSE 1 study. The results confirm #lenacapavir demonstrated 100% efficacy for #HIV prevention in cisgender women.

In the PURPOSE 1 randomized, controlled trial involving women in South Africa & Uganda, twice-yearly subcutaneous lenacapavir was superior to daily oral emtricitabine–tenofovir disoproxil fumarate in preventing HIV infection. Full trial results: nej.md/3zRElVj #AIDS2024

Zero is zero!!! Remarkable results of injectable lenacapavir for PrEP. Now we must translate trial results into public health impact. #AIDS2024 @LindaGailBekker @apha_sa @ICWEastAfrica

“The introduction of oral #PrEP has changed the lives of more than 6 million people globally who have accessed it.” - @iasociety Past President @LindaGailBekker 🇿🇦 #AIDS2024

📊 Today at #AIDS2024, Past IAS President @LindaGailBekker presents full results from PURPOSE 1 trial. The results confirm #lenacapavir demonstrated 100% efficacy for #HIV prevention in cisgender women. Read IAS President & AIDS 2024 Int'l Co-Chair @ProfSharonLewin's statement.

When science listens to community it looks something like this. We Join the AWPCAB and The Purporse1 GGCAG in celebrating the science and most importantly the trial participants . #Purpose1 #Choice #AGYW #AWPCAB awpcab.org/2024/06/21/sta…

Gilead's twice-yearly antiviral protected women from HIV infection. PURPOSE 1 study results seem to be fantastic. ⁦@statnews⁩ statnews.com/2024/06/20/hiv…

@TheNickFoy 😂😂😂

Anyway, thoughts and prayers for everyone in the Bay Area. 🙏🏼

We are weak people.

@ajlamesa I think this is a great idea and wish there were both higher age limits and a commitment by governments and tech companies to developing high quality secure methods for age verification

Not a terrible idea, but very difficult to enforce.

We are deeply saddened by the passing of Adaora Adimora, MD, MPH, FIDSA. We were incredibly fortunate for her dedication to @IDSAinfo & HIVMA.

Can’t believe the Spurs took Wemby over Podz.

Today is World AIDS Day and after 32 years of living with HIV, I’m blessed to still be here! I’m proud of the progress made in HIV/AIDS research, medication, and funding. We still have a long way to go for a cure and in the fight against stigma in all communities, especially in Black and brown. There is no place in this world for discrimination against those living with HIV/AIDS. #WorldAIDSDay

lol...this is why my parents made sure I got my driver's license 3 days after I turned 16

@khmayer1 @michael_traeger @JuliaLMarcus @douglaskrakower Great article! Really like the shift from stigmatizing language around “risky behavior” to affirming positive impacts of PrEP use

#PrEP uptake is suboptimal. One problem is the difficulty providers have in supporting their patients' #sexual well-being. @michael_traeger @JuliaLMarcus @douglaskrakower and I discuss how to prioritize patients' experiences in this week's @LancetHIV sciencedirect.com/science/articl…